Page 58 - Approval Program News Today

FN Media Group Presents USA News Group News Commentary VANCOUVER, British Colombia, Dec. 1, 2022 /PRNewswire/ -- USA News Group - A series of new Fast Track designations have been handed

/PRNewswire/ -- USA News Group - A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this...

The manufacturer has voluntarily withdrawn the US indication that covered its use in certain patients with bladder and urinary tract cancers.

Tecentriq failed to beat chemotherapy in improving overall survival, the main goal of its confirmatory Phase 3 test in bladder cancer. The drug had been granted accelerated approval based on results from a single-arm Phase 2 clinical trial.

MADISON, Wis. – Attorney General Josh Kaul today announced that the Wisconsin Department of Justice (DOJ) obtained a court order that immediately prohibits Pr

Significant Necrosis Demonstrated in Invasive Ductal and Lobular Cancers, Which are Normally Resistant to Chemotherapy. Significant Necrosis from a Single...

/PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today...

Cui bono is Latin for "Who benefits?" Its the sister phrase of "sequi pecuniam/follow the money" and the orphan of "plebes/the people." All roads used to lead to Rome. Today, they lead to chosen industry. There are many sayings about...

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting...

/PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that...